ClinicalTrials.gg
CompletedNCT00985348Updated May 16, 2012

Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)

A Phase 1 interventional study of Levetiracetam (Keppra) in Healthy, sponsored by UCB Pharma. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-05-16.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

To demonstrate the bioequivalence of a Levetiracetam dry syrup (50% (500mg/1000mg)) versus Levetiracetam 500 mg oral tablet, used as reference, after single dose administration in healthy Japanese subjects.

02

Conditions studied

  • Healthy

Keywords

  • Levetiracetam
  • Healthy volunteers
  • Healthy Subjects
03

In context

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written dated and signed by subject.
  • Healthy male or female Japanese volunteer from the first generation, living outside of Japan for less than 10 years, age range 20 to 55 years inclusive.
  • (BMI) between 18.0 and 28.0 kg/m² inclusive.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating or sexually active women with who are not using a medically accepted method.
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, neurological, psychiatric disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication.
  • History of drug addiction or presence of drug addiction (positive drug screen) or excessive use of alcohol (weekly intake in excess of 21 units alcohol for male and 14 units alcohol for female; one unit alcohol equals one glass of beer or lager, a glass of wine or a measure of spirits), of psychological or other emotional problems that are likely to invalidate , or limit the ability of the subject to comply with the protocol requirements.
  • Heavy caffeine drinker (drinking >5 cups of coffee or equivalent, approximately 500mg of caffeine per day).
  • Smokers of more than 10 cigarettes per day or smokers not willing to abstain from smoking while in the clinic for each period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment 1/Treatment 2

    Drug: Levetiracetam (Keppra)

  • Experimental
    Treatment 2/Treatment 1

    Drug: Levetiracetam (Keppra)

Interventions

  • Test Drug : Levetiracetam dry syrup Reference Drug : 500 mg oral tablets of Levetiracetam. Frequency: Single Dose

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Cmax (maximum plasma concentration) of Levetiracetam.

    Time frame: 36 hours

  2. AUC (0-t) (Area under the plasma concentration vs. time curve observed from time 0 h up to the last measurable data point) of Levetiracetam

    Time frame: 36 hours

  3. AUC (Area under the curve extrapolated to infinity) of Levetiracetam

    Time frame: 36 hours

Secondary outcomes

  1. tmax (time of maximum plasma concentration) of Levetiracetam

    Time frame: 36 hours

  2. λz (Terminal elimination rate constant) of Levetiracetam

    Time frame: 36 hours

  3. t1/2 (Terminal elimination half-life) of Levetiracetam

    Time frame: 36 hours

  4. MRT (Mean Residence Time) of Levetiracetam

    Time frame: 36 hours

  5. CL/F (Apparent total body clearance) of Levetiracetam

    Time frame: 36 hours

  6. Vz/F (Apparent volume of distribution) of Levetiracetam

    Time frame: 36 hours

07

Study locations

1 site
  • London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2009
First posted
Sep 28, 2009
Start
Sep 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Last update
May 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00985348
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 28, 2009
Start date
Sep 2009
Primary completion
Oct 2009
Completion
Oct 2009
Last update
May 16, 2012

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion